Inventor
John BUELL
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07DHeterocyclic compounds32%
C07KPeptides5%
PatentTitleYear
12,509,444Compounds and methods for CD73 modulation and indications therefor202512,202,818Compounds and methods for CD73 modulation and indications therefor202512,091,426Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof202411,807,626Compounds and methods for CD73 modulation and indications therefor202311,739,101Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof202311,446,287Compounds and methods for EP300 or CBP modulation and indications therefor202211,149,011Compounds and methods for IDO and TDO modulation, and indications therefor2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2025Patents assigned to PLEXXIKON INC (2)· patent assignee history
2021–2025Based in US· patent location history
2022Patents assigned to OPNA IMMUNO ONCOLOGY SA (1)· patent assignee history
2023–2024Patents assigned to GILEAD SCIENCES INC (2)· patent assignee history
2023–2024Patents assigned to NURIX THERAPEUTICS INC (2)· patent assignee history
2023–2025Patents assigned to Opna Bio SA (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GILEAD SCIENCES INC | 2 | 2023–2024 |
| NURIX THERAPEUTICS INC | 2 | 2023–2024 |
| Opna Bio SA | 2 | 2023–2025 |
| PLEXXIKON INC | 2 | 2021–2025 |
| OPNA IMMUNO ONCOLOGY SA | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2021–2025 |